Mochida Pharmaceutical Co., Ltd.

TSE:4534 Stock Report

Market Cap: JP¥124.8b

Mochida Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Mochida Pharmaceutical's earnings have been declining at an average annual rate of -3.2%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 0.08% per year. Mochida Pharmaceutical's return on equity is 3.5%, and it has net margins of 4.3%.

Key information

-3.2%

Earnings growth rate

-1.6%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate0.08%
Return on equity3.5%
Net Margin4.3%
Next Earnings Update07 Feb 2025

Recent past performance updates

Recent updates

Mochida Pharmaceutical (TSE:4534) Is Due To Pay A Dividend Of ¥40.00

Dec 04
Mochida Pharmaceutical (TSE:4534) Is Due To Pay A Dividend Of ¥40.00

Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Sep 06
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00

Aug 22
Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00

Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Aug 08
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00

Jul 25
Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00

Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Jul 11
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00

Mar 22
Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00

Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Mar 02
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00

Revenue & Expenses Breakdown

How Mochida Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4534 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24104,5054,53433,64212,554
30 Jun 24103,5454,41333,79012,554
31 Mar 24102,8854,54733,71312,554
31 Dec 23100,0853,01234,05913,283
30 Sep 2399,5375,56431,73813,283
30 Jun 23100,3165,18233,02113,283
31 Mar 23103,2616,64933,32413,283
31 Dec 22106,7598,47032,89912,295
30 Sep 22109,3709,57633,21812,295
30 Jun 22110,50911,07132,08612,295
31 Mar 22110,17910,56932,86612,295
31 Dec 21107,92810,36033,96710,849
30 Sep 21105,3818,09234,83410,849
30 Jun 21102,9787,87333,90710,849
31 Mar 21102,9958,58731,93910,849
31 Dec 20102,5836,62730,51711,884
30 Sep 20101,9105,41730,74011,884
30 Jun 20102,6904,66031,41811,884
31 Mar 20101,7994,59831,22811,884
31 Dec 19101,1024,96431,36613,003
30 Sep 19103,9196,09130,28413,003
30 Jun 19106,3315,89730,66513,003
31 Mar 19109,6438,43530,58113,003
31 Dec 18110,6699,60230,60211,912
30 Sep 18109,40910,03730,77011,912
30 Jun 18107,55010,54829,84911,912
31 Mar 18106,7619,02329,99211,912
31 Dec 17108,0428,00129,26615,226
30 Sep 17105,5118,88628,70715,226
30 Jun 17101,8529,56928,48915,226
31 Mar 1797,3498,52629,71015,226
31 Dec 1693,1409,54729,76413,454
30 Sep 1693,3378,89730,18313,454
30 Jun 1694,1388,22630,81713,454
31 Mar 1692,2728,15029,39113,454
31 Dec 1592,1389,44928,92111,777
30 Sep 1590,2009,26228,01811,777
30 Jun 1589,4678,82329,13111,777
31 Mar 1587,2527,54429,88111,777
31 Dec 1489,5297,88131,56111,961
30 Sep 1491,0378,58532,20911,961
30 Jun 1492,0159,87231,13911,961
31 Mar 1493,9479,89231,02611,961

Quality Earnings: 4534 has high quality earnings.

Growing Profit Margin: 4534's current net profit margins (4.3%) are lower than last year (5.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4534's earnings have declined by 3.2% per year over the past 5 years.

Accelerating Growth: 4534's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4534 had negative earnings growth (-18.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.2%).

Return on Equity

High ROE: 4534's Return on Equity (3.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/01 17:35
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mochida Pharmaceutical Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Toshiyuki HibinoMitsubishi UFJ Morgan Stanley Securities Company Limited
Taku OuchiSMBC NIKKO
Jayaprabha DhavaleVirtua Research Inc.